FY2025 EPS Estimates for Novavax Increased by Zacks Research

Novavax, Inc. (NASDAQ:NVAX) – Zacks Research increased their FY2025 EPS estimates for Novavax in a research note issued on Tuesday, January 28th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings per share of ($0.72) for the year, up from their prior estimate of ($0.77). The consensus estimate for Novavax’s current full-year earnings is ($1.31) per share.

Several other research firms have also commented on NVAX. Jefferies Financial Group dropped their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. Finally, B. Riley reissued a “buy” rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Novavax presently has an average rating of “Hold” and an average target price of $17.83.

Novavax Price Performance

Shares of NASDAQ NVAX opened at $9.01 on Friday. Novavax has a 1-year low of $3.53 and a 1-year high of $23.86. The business’s 50 day moving average is $8.81 and its two-hundred day moving average is $10.84.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to analysts’ expectations of $65.80 million. The business’s quarterly revenue was down 54.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.26) earnings per share.

Insider Transactions at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares of the company’s stock, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is currently owned by company insiders.

Institutional Trading of Novavax

A number of institutional investors have recently modified their holdings of NVAX. Charles Schwab Investment Management Inc. lifted its position in Novavax by 16.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company’s stock valued at $16,741,000 after acquiring an additional 187,548 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Novavax by 26.7% during the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after purchasing an additional 517,727 shares during the last quarter. State Street Corp boosted its position in shares of Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after purchasing an additional 1,621,772 shares in the last quarter. Vontobel Holding Ltd. grew its stake in Novavax by 110.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company’s stock worth $6,296,000 after buying an additional 261,464 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in Novavax by 300.4% in the third quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company’s stock valued at $1,226,000 after buying an additional 72,894 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.